170 related articles for article (PubMed ID: 16462768)
1. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma.
Sensi M; Nicolini G; Petti C; Bersani I; Lozupone F; Molla A; Vegetti C; Nonaka D; Mortarini R; Parmiani G; Fais S; Anichini A
Oncogene; 2006 Jun; 25(24):3357-64. PubMed ID: 16462768
[TBL] [Abstract][Full Text] [Related]
2. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.
Petti C; Molla A; Vegetti C; Ferrone S; Anichini A; Sensi M
Cancer Res; 2006 Jul; 66(13):6503-11. PubMed ID: 16818621
[TBL] [Abstract][Full Text] [Related]
3. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
4. Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice.
Uguen A; Guéguen P; Legoupil D; Bouvier S; Costa S; Duigou S; Lemasson G; Ledé F; Sassolas B; Talagas M; Férec C; Le Maréchal C; De Braekeleer M; Marcorelles P
Hum Pathol; 2015 Nov; 46(11):1582-91. PubMed ID: 26297254
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of human cutaneous melanoma-derived cell lines.
Ogbah Z; Puig-Butille JA; Simonetta F; Badenas C; Cervera R; Milá J; Benitez D; Malvehy J; Vilella R; Puig S
Anticancer Res; 2012 Apr; 32(4):1245-51. PubMed ID: 22493355
[TBL] [Abstract][Full Text] [Related]
6. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
7. Involvement of overexpressed wild-type BRAF in the growth of malignant melanoma cell lines.
Tanami H; Imoto I; Hirasawa A; Yuki Y; Sonoda I; Inoue J; Yasui K; Misawa-Furihata A; Kawakami Y; Inazawa J
Oncogene; 2004 Nov; 23(54):8796-804. PubMed ID: 15467732
[TBL] [Abstract][Full Text] [Related]
8. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
[TBL] [Abstract][Full Text] [Related]
9. Sema6A and Mical1 control cell growth and survival of BRAFV600E human melanoma cells.
Loria R; Bon G; Perotti V; Gallo E; Bersani I; Baldassari P; Porru M; Leonetti C; Di Carlo S; Visca P; Brizzi MF; Anichini A; Mortarini R; Falcioni R
Oncotarget; 2015 Feb; 6(5):2779-93. PubMed ID: 25576923
[TBL] [Abstract][Full Text] [Related]
10. Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.
Burd CE; Liu W; Huynh MV; Waqas MA; Gillahan JE; Clark KS; Fu K; Martin BL; Jeck WR; Souroullas GP; Darr DB; Zedek DC; Miley MJ; Baguley BC; Campbell SL; Sharpless NE
Cancer Discov; 2014 Dec; 4(12):1418-29. PubMed ID: 25252692
[TBL] [Abstract][Full Text] [Related]
11. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
Lee JH; Choi JW; Kim YS
Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657
[TBL] [Abstract][Full Text] [Related]
12. Absence of BRAF and NRAS mutations in uveal melanoma.
Cruz F; Rubin BP; Wilson D; Town A; Schroeder A; Haley A; Bainbridge T; Heinrich MC; Corless CL
Cancer Res; 2003 Sep; 63(18):5761-6. PubMed ID: 14522897
[TBL] [Abstract][Full Text] [Related]
13. NRAS and BRAF mutation frequency in primary oral mucosal melanoma.
Buery RR; Siar CH; Katase N; Gunduz M; Lefeuvre M; Fujii M; Inoue M; Setsu K; Nagatsuka H
Oncol Rep; 2011 Oct; 26(4):783-7. PubMed ID: 21750866
[TBL] [Abstract][Full Text] [Related]
14. Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions.
Indsto JO; Kumar S; Wang L; Crotty KA; Arbuckle SM; Mann GJ
J Cutan Pathol; 2007 Jun; 34(6):448-55. PubMed ID: 17518771
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
Saldanha G; Potter L; Daforno P; Pringle JH
Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
[TBL] [Abstract][Full Text] [Related]
16. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance.
Da Forno PD; Pringle JH; Fletcher A; Bamford M; Su L; Potter L; Saldanha G
Br J Dermatol; 2009 Aug; 161(2):364-72. PubMed ID: 19438459
[TBL] [Abstract][Full Text] [Related]
17. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis.
Willmore-Payne C; Holden JA; Tripp S; Layfield LJ
Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115
[TBL] [Abstract][Full Text] [Related]
18. Microarray expression profiling in melanoma reveals a BRAF mutation signature.
Pavey S; Johansson P; Packer L; Taylor J; Stark M; Pollock PM; Walker GJ; Boyle GM; Harper U; Cozzi SJ; Hansen K; Yudt L; Schmidt C; Hersey P; Ellem KA; O'Rourke MG; Parsons PG; Meltzer P; Ringnér M; Hayward NK
Oncogene; 2004 May; 23(23):4060-7. PubMed ID: 15048078
[TBL] [Abstract][Full Text] [Related]
19. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9.
Kumar R; Angelini S; Hemminki K
Oncogene; 2003 Dec; 22(58):9217-24. PubMed ID: 14681681
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.
Devitt B; Liu W; Salemi R; Wolfe R; Kelly J; Tzen CY; Dobrovic A; McArthur G
Pigment Cell Melanoma Res; 2011 Aug; 24(4):666-72. PubMed ID: 21615881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
